- CytRx (CYTR) is out with some interim data from a Phase 2b trial of aldoxorubicin versus doxorubicin as a first-line treatment for advanced soft tissue sarcomas.
- ORR for the aldoxorubicin group was 22% versus 0% for the doxorubicin group and CYTR says only 32% of patients that received aldoxorubicin experienced progressive disease versus 50% of patients who received doxorubicin.
- SAEs: 24 for aldoxorubicin versus 6 for doxorubicin (ultimately, none of the SAEs required discontinuation of treatment).
- Top-line PFS data is expected in December. (PR)
- CYTR +2% premarket
at MarketWatch.com (Dec 11, 2013)